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Visual Contrast Sensitivity as
a Diagnostic Tool 
In “Possible Estuary-Associated Syndrome:
Symptoms, Vision, and Treatment,”
Shoemaker and Hudnell (1) advocated use
of the visual contrast sensitivity (VCS) test
as a biomarker to diagnose possible estuary-
associated syndrome (PEAS) and to assess
response to their proposed treatment
regimen. However, the use of VCS as a
diagnostic test for PEAS (and subsequent
treatment of PEAS with cholestyramine) is
not supported by a careful examination of
the existing evidence. These points should
be clarified. 
Shoemaker and Hudnell (1) made indi-
rect reference to my work (2) in citing
Hudnell’s publication that suggested a statis-
tical association between VCS deficits in
estuary watermen and hours spent at fish
kills (3). In this paper Hudnell et al. (3) used
our medical data and their vision data, but
reached some conclusions that are not whol-
ly supported by the original historical data.
For example, Hudnell et al. (3) ruled out the
possibility that observed VCS deficits could
be due to known neurotoxicants such as sol-
vents or metals, on the basis of our occupa-
tional and environmental history responses.
These responses were qualitative only and
were not sufficiently detailed to distinguish
between gasoline poured into a fuel tank
(reported by most fishermen) and that used
as hand-cleaner (reported by some fisher-
men). The history elicited did not fully
document exposure to other specific and
potentially neurotoxic substances that might
be found in estuaries, such as hydrogen sul-
fide from decaying organic materials. [These
omissions have been addressed in the cur-
rent cohort studies in North Carolina (4).]
Hudnell et al.’s alternative hypothesis (3),
that the VCS deficits may be
caused by unknown, non-exposure-related fac-
tor(s) or by some other, perhaps more continu-
ous exposure factor(s) associated with the estuar-
ies or geographical area (p. 590)
is more tenable, as is his comment that
“given the multiple potential explanations
and the study limitations, each of these
possibilities should be viewed as tentative
(p. 590). Hudnell does concede that in this
work, “few study participants met the
[Centers for Disease Control and
Prevention] case definition for PEAS” (3;
p. 590). Actually, no subjects met the case
description for active PEAS; the prevalence
of past symptoms consistent with PEAS was
equal in the estuary (exposed) and offshore
(unexposed) watermen and consisted of one
individual in each group. This suggests that
neither current active nor past history of
PEAS is likely to be the reason for the
intergroup differences in VCS in the estu-
ary versus offshore watermen. 
In addition, the (P)EAS description is
an epidemiologic concept, meant primarily
for surveillance and enumeration purposes.
Epidemiologists frequently adopt these
concepts to identify potential cases for fur-
ther clinical evaluation. The description
does not represent diagnostic criteria, but is
an indication for further evaluation. These
descriptions are used to “cast a wide net”
and do not indicate that disease is present
until further testing verifies a diagnosis.
VCS is an indicator of a subclinical process
and is not a diagnostic test.
In a study in Virginia, Turf et al. (5) did
not identify any cases of EAS in the first
year of their ongoing prospective cohort
study. They observed VCS deficits, which
correlated with age, exposure time to estu-
ary waters where Pfiesteria organisms may
be found more than 50% of the time, and
smoking. However, these deficits were not
correlated with active (P)EAS, “as no cases
were identified during the study. No toxic
Pfiesteria events nor changes in neurocogni-
vive function were observed” (5). Data are
accumulating that Pfiesteria is enzootic in
Atlantic coastal waters, even where ichthy-
otoxic effects have never been observed.
The presence of the organism is not equiva-
lent to presence of its secreted biotoxin,
which is produced under rare, and current-
ly incompletely defined, environmental
conditions (6).
Other studies in North Carolina have
evaluated telephone hotline callers with
self-reports of symptoms and exposures
potentially related to PEAS. As a group, the
self-identified “cases” had normal VCS and
the control subjects (predominantly non-
watermen) had VCS abnormalities (7).
Hudnell (8) concluded that VCS data in
this case–control series “do not indicate
that visual function was affected by expo-
sure to North Carolina estuaries” (p. 16). 
Hudnell et al. (3) stated that VCS may
be a useful indicator for the diagnosis of
PEAS, citing the work of Shoemaker and
Hudnell (1) as evidence, while Shoemaker
and Hudnell (1) cited Hudnell et al. (3) to
support the use of VCS as a diagnostic test,
setting up a circular pattern of reasoning.
VCS has never been validated as having
any correlation to the neuropsychologic
(NP) deficits seen in Maryland (9,10). The
Maryland cases represent the only docu-
mented, fully evaluated cluster of environ-
mental PEAS cases to date. Shoemaker and
Hudnell (1) did not obtain NP testing on
their subjects, although this represents the
current “gold standard” for verifying PEAS;
thus, this is a major shortcoming in their
work. [One subject described by Shoemaker
and Hudnell (1) had been part of the
Maryland cohort and was fully evaluated in
that context (9). That his NP scores were
normal on 3-month follow-up by the
Maryland research team is not unique or
attributable to a specific treatment regi-
men. Most affected persons in Maryland
improved over 3–6 months without any
treatment (11)]. Symptoms such as confu-
sion and memory problems are seen in a
wide variety of clinical situations, ranging
from neurotoxin exposure to sick building
syndrome to emotional distress. Such symp-
toms indicate the need for further evalua-
tion and full characterization before the
initiation of treatment. VCS is a nonspecif-
ic test for neurologic function, which hap-
pens to be sensitive to some neurotoxin
exposures, such as polychlorinated
biphenyls and styrene. It is also affected by
common conditions such as alcohol and
medication use, learning disabilities,
Parkinsonism, Alzheimer’s dementia, vita-
min deficiencies, and multiple sclerosis (7).
An advertisement for Shoemaker’s lat-
est book, Desperation Medicine (12), in the
Carnrick (Pharmaceuticals) Quarterly news-
paper (13) describes 
how a family practice doctor discovered the neu-
rotoxin basis of chronic Lyme disease, sick build-
ing syndrome, Pfiesteria, ciguatera and other
chronic illnesses (p. 20), 
and that 
… a physiologic test of contrast sensitivity pin-
points the true neurotoxic cause of symptoms
which are often incorrectly passed off as depres-
sion, fibromyalgia, stress and IBS [irritable bowel
syndrome] (p. 20). 
A successful treatment regimen is promised
to readers (13). Shoemaker also advocates
the use of VCS to screen all patients “who
want [the] Lymerix” vaccination for Lyme
disease at his chronic fatigue center (14); he
has written that “many asymptomatic
patients with a history of Lyme … have the
VCS deficit” (14). On his Web site, “Visual
Contrast Sensitivity Test Center” (15),
Shoemaker stated that 
Neurotoxin forming algae are being identified
nearly monthly. If you do not have the VCS
deficit, response to binding therapy is less [than]
66%. If you have the VCS deficit, response to
therapy is over 90%.
He also stated that “unexplainable recurring
joint pains of hands, wrists and/or feet” is
another symptom of neurotoxin poisoning.
Also on this Web site (15), Shoemaker dis-
cussed the use of the VCS exam to diagnose
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green algae in central Florida), sick building syn-
drome, Lyme disease, and soon chronic fatigue
syndrome and chronic soft tissue pathways when
our clinical data reach statistical certainty. 
He stated that papers on ciguatera, sick
building syndrome, and Lyme disease were
being prepared, but we have not found these
reports in a publications database to date.
On the basis of this evidence, it can only
be concluded that a) VCS abnormalities are
so widespread and nonspecific as to have
limited usefulness as a biomarker for any
particular condition (especially in the
absence of industrial hygiene or environ-
mental documentation regarding the source
of exposure); and b) there is no evidence that
VCS deficits have been observed in persons
with current active PEAS verified by accept-
ed, objective NP tests. Of note, passive sur-
veillance efforts to detect PEAS have not
recorded any verified cases (16) through
2000. Health-care providers have been asked
to report suspected PEAS cases to their
county health departments in Delaware,
Florida, Maryland, North Carolina, South
Carolina, and Virginia. The health depart-
ments can facilitate the full evaluation of
these cases, including NP testing through
state health agencies. We hope that the read-
ers of EHP will recognize the anecdotal and
unsubstantiated nature of the reports in the
paper by Shoemaker and Hudnell (1), as
well as the tremendous amount of medical
research yet to be done before either VCS as
a biomarker or cholestyramine as a treat-
ment can be appropriately advocated.
Marian Swinker
William A. Burke
East Carolina University School of Medicine
Greenville, North Carolina
E-mail: swinkerm@mail.ecu.edu 
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Visual Contrast Sensitivity:
Response 
We are pleased to respond to the letter from
Swinker and Burke regarding our paper
“Possible Estuary-Associated Syndrome:
Symptoms, Vision, and Treatment” (1),
which was published in EHP as a Grand
Rounds in Environmental Medicine article.
Swinker and Burke state that “the use of
VCS as a diagnostic test for PEAS (and
subsequent treatment of PEAS with
cholestyramine) is not supported by a care-
ful examination of the existing evidence.”
Their letter, however, does not discuss the
data presented for the five Grand Rounds
cases; they mention only our Case 1, and
that is in reference to the patient’s partici-
pation in the Maryland study on exposure
to waterways containing toxin-producing
Pfiesteria (2). We agree that previous publi-
cations only associated a VCS deficit with
Pfiesteria-inhabited estuary contact, not
with active PEAS. The North Carolina
study, which associated the VCS deficit
with estuarine contact (3,4), was designed
to investigate the potential for persistent,
estuary-associated health effects (5). Unlike
the Maryland study, which involved recent
exposure to fish kills and active PEAS (2),
members of the North Carolina estuary
cohort had no recent fish-kill exposure and
were not selected because of complaints of
current health effects (5). The North
Carolina study (5) attempted to use the
Centers for Disease Control and Prevention
(CDC) symptom-based case definition (6)
to assess PEAS at remote times of fish kill
or lesioned fish contact, times at which
VCS data were unavailable (5). The
Virginia study (7) verified the VCS deficit
in people contacting estuaries inhabited by
“Pfiesteria-like organisms,” but reported no
active PEAS cases. Neither the North
Carolina nor the Virginia study reported
the prevalence of current PEAS symptoms
in the exposed or control populations (5,7).
The Grand Rounds cases, therefore, repre-
sent the first reports of VCS data measured
before and during active PEAS diagnosis
and after successful treatment (1). The dra-
matic and concurrent variations in VCS
with the presence and absence of symptoms
suggested that VCS measurements are a
useful adjunct to the PEAS case definition.
In the Grand Rounds article, we careful-
ly described the PEAS diagnostic criteria,
involving exposure potential, symptoms, and
the lack of alternative explanations. We mea-
sured VCS in Cases 2–5 to assess its useful-
ness in aiding PEAS diagnosis and recovery
monitoring (1). All cases became ill shortly
after exposure to estuaries in which Pfiesteria
was identified and after dead or lesioned fish
were observed. The cases initially had
depressed VCS and multiple symptoms,
including many of those listed by the CDC
in the PEAS case definition, as well as the
others reported (1). All cases had no history
of illness involving neurologic dysfunction,
allergy, asthma, eosinophilia, or neurotoxi-
cant exposure. Complete blood count, com-
prehensive metabolic profile, and pulmonary
function test results were within normal
parameters. The pattern of VCS recovery
and symptom resolution promptly following
initiation of cholestyramine (CSM) therapy
seen in all cases was documented prospec-
tively in Case 2 (a researcher). His fall in
VCS and symptom onset occurred within
36 hr of exposure to a site where a fish kill
occurred 2 days later, and with very low
probability of exposure to nonestuarine-
associated neurotoxicants. Collectively, the
cases demonstrated similar, large VCS deficits
in acute, chronic, and repeated-acquisition
illness, and subsequent rapid return to normal
VCS coincident with CSM treatment.
The lack of significant exposure to
known solvents in the Grand Rounds cases
and the VCS recovery with treatment
strongly argued that neither the symptoms
nor VCS deficits were caused by solvent
exposure. Solvent-induced symptoms and
deficits in VCS and neurobehavioral perfor-
mance are persistent or permanent, having
been measured long after cessation of solvent
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exposure (8–10). We found no literature on
recovery from solvent- or other toxicant-
induced VCS deficits. Symptomatic patients
with occupational solvent exposure and VCS
deficits did not respond to CSM treatment
(11). The concern of possible hydrogen sul-
fide exposure, mentioned by Swinker and
Burke, is highly unlikely to be a causative
factor for VCS deficits in watermen who
work outdoors without occupational expo-
sure to sources of H2S, such as submerged,
decaying sediments of marshes.
Our most recent data, presented at the
CDC National Conference on Pfiesteria
(12) and published in EHP (13), confirmed
the observations reported in the Grand
Rounds article (1) in a population of 77
patients with residential and/or recreational
exposure to Pfiesteria-inhabited estuaries in
Maryland (13). Relative to two control pop-
ulations totaling 87 patients, one with resi-
dential and/or recreational exposure to
marine waters and one with no exposure to
any bodies of water, the estuary cohort
showed significantly depressed VCS.
Thirty-seven members of the estuary cohort
met the CDC case definition for PEAS (6).
The 60% loss of VCS in the PEAS cases
accounted for the entire VCS difference
between the estuary and combined-control
cohorts. VCS recovered to control levels as
symptoms resolved within 2 weeks of CSM
treatment. Shoemaker (13) also presented
results from an earlier small, double-blind-
ed, placebo-controlled, crossover clinical
trial that showed the efficacy of CSM treat-
ment in PEAS and the lack of a placebo
effect. He also presented data indicating
that repeated testing does not alter VCS
scores and that CSM has no effect on VCS
in non-PEAS patients treated for hyper-
cholesterolemia (13).
Swinker and Burke refer to neuropsycho-
logic tests as the “‘gold standard’ for verifying
PEAS.” This is curious because neuropsycho-
logic test deficits are nonspecific, and
Swinker and Burke object to the use of VCS
testing in PEAS diagnosis because VCS
deficits are nonspecific. We think that all
tests which objectively describe neurologic
deficits in symptom-described illness may
assist in diagnosis, particularly when preexpo-
sure data are available. Issues of neuropsycho-
logic testing availability in rural areas,
patients’ willingness to spend 3–4 hr in test-
ing, and individual diagnosis criteria must be
confronted, however, before neuropsycholog-
ic tests can become a gold standard for prac-
ticing physicians. The VCS data presented in
the Grand Rounds article (1) showed
40–90% fluctuations between wellness and
illness that occurred within days in individual
cases. The VCS test provided a rapid, inex-
pensive, and readily available objective 
indicator that was strongly associated with
corresponding changes in symptoms. All
VCS deficits were outside the range of our
(unpublished) age-adjusted, normative data.
Neither the Maryland study (2), our
Grand Rounds article (1), nor our recent
paper (13) definitively attributed illness to
Pfiesteria-toxin(s) exposure. Definitive attri-
bution of PEAS causation to Pfiesteria
toxin(s), if that is the case, must await the
identification of the toxin or toxins pro-
duced by Pfiesteria, detection of the toxin(s)
in ill patients, and the absence of the toxin(s)
in recovered patients. Recent research by
Kimm-Brinson et al. (14) reported that a
partially isolated toxin from Pfiesteria is an
agonist for the adenosine-5´-triphosphate
P2X7 receptors found in the membranes of
microglia and peripheral macrophages.
Activation of P2X7 receptors triggers a
proinflammatory cytokine response that
could potentially account for the Pfiesteria-
related effects observed in humans and
wildlife. The hypothesis that direct
Pfiesteria-toxin(s) effects, combined with
downstream cytokine effects (in the absence
of abnormalities in standard immunologic
system test results), are the sources of symp-
toms in PEAS cases should be pursued.
We wish to address several other issues
raised by Swinker and Burke. They are cor-
rect in quoting Hudnell (3) on the hotline-
caller data from the North Carolina study.
The VCS data “do not indicate that visual
function was affected by exposure to North
Carolina estuaries” (p. 19). Swinker and
Burke did not mention,
however, the potentially
confounding factors con-
cerning characteristics of
the hotline callers and
their control group that
may be responsible for the
lack of association. First,
of the 11 hotline callers
assessed, Swinker et al.
(15) subsequently report-
ed that only 6 were found
to have “relevant fish or
water exposure,” that only
6 had “actual” exposure
(pp. 129–130). Second,
analyses done at Swinker’s
request suggested VCS
“abnormality” in the six
cases with “relevant” or
“actual” exposure (Figure
1). In fact, their VCS was
at or below the level of
the occupational estuary
cohort (3,4) at all spatial
frequencies. Swinker et
al. (15) reported that only
these six cases with actual
exposure met the CDC criteria for estuary-
associated syndrome, and that four had neu-
ropsychologic impairment. They dismissed
the diagnoses of estuary-associated syn-
drome, saying that “All six exposed cases had
underlying or pre-existing medical condi-
tion(s) that could explain at least some of
their symptoms” (15). 
We submit that the description “could
explain at least some of their symptoms” is
insufficient for dismissing the diagnosis in
situations where the VCS deficit is present
and CSM treatment would clarify the issue.
Third, the four callers without actual expo-
sure, for whom VCS could be assessed,
showed “normal” values (Figure 1)—values
similar to those of the control offshore
cohort (3,4). Fourth, VCS appeared to be
“abnormal” in the hotline-caller control
cohort (Figure 1). Of the 10 controls for
whom VCS could be assessed, all reported
exposures to North Carolina estuaries
(recreational, n = 10; occupational, n =3 ;
living by the estuaries, n = 2), and 8 report-
ed solvent exposure (occupational, n = 5;
avocational, n = 4). Comparison of the VCS
data for the entire hotline-caller cohort with
that of the hotline-caller control cohort (3),
therefore, did not give evidence of an estu-
ary-associated VCS deficit in the callers,
perhaps due to a confounding of relevant
exposures between groups.
Swinker and Burke note that the CDC
(16) did not receive reports of any verified
cases of PEAS through 2000 but that “the
health departments can facilitate the full
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Figure 1. VCS functions (mean ± SEM) for five groups. The VCS deficit in
the potentially exposed estuary cohort, statistically significant relative to
the offshore cohort, was previously published (3,4) and is shown as a ref-
erence for the other groups. The VCS function for the nonexposed hotline
callers (callers with no “actual” or “relevant” exposure as defined by
Swinker) is similar to that of the unexposed offshore cohort, whereas the
VCS values of the exposed hotline callers (callers with “actual” or “rele-
vant” exposure as defined by Swinker) are at or below those of the estu-
ary cohort at each spatial frequency. The VCS function for the hotline
controls, who reported confounding estuary (n = 10) and solvent (n = 8)
exposures, is similar to that of the estuary cohort. Estuary exposure,
therefore, was associated with low VCS scores in the estuary cohort, the
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evaluation of cases.” The State of Maryland
Pfiesteria Surveillance Team announced
that it had identified five patients meeting
the CDC PEAS criteria from 1997 to 2000
(17). We commend the Maryland team and
hope that our publications on PEAS will
assist other health-care professionals in iden-
tifying PEAS cases.
Swinker and Burke omitted the quota-
tion marks around “asymptomatic” in an e-
mail message written by Shoemaker (18),
which referred to patients with arthritic and
biotoxic symptoms following dosages of the
Lyme vaccine. The point Shoemaker made
was that among patients who wanted the
Lymerix vaccine following treatment with
antibiotics for Lyme disease, there were many
who had persistent symptoms attributed,
perhaps inappropriately, to other illnesses.
Shoemaker’s data suggest that the persistent
symptoms may represent another biotoxin-
induced illness, post-Lyme syndrome. The
patients’ history of Lyme disease, the persis-
tence of symptoms following substantial
antibiotic treatment, the continued presence
of a VCS deficit, and VCS recovery concur-
rent with symptom resolution after CSM
treatment suggest that the bacteria may have
released toxins before and/or during cell lysis.
Patients inappropriately labeled as “cured” or
“asymptomatic” are at a significant risk, in
Shoemaker’s opinion, of possible adverse
effects from the Lymerix vaccine due to
potentiation of a proinflammatory cytokine
response. An accurate quote of the full sen-
tence does not suggest that truly asympto-
matic patients have a VCS deficit (18), as
Swinker and Burke imply. If VCS deficits
were as common as they imply, then it is
unlikely that VCS testing would have been so
successful in distinguishing toxin-affected or
clinical groups from normal [see references in
Shoemaker (13)].
Swinker and Burke indirectly criticize
Shoemaker’s Web site (19), which is still
under construction. We thank them for
pointing out typographical errors and regret
that we have not yet had the time to com-
plete manuscripts that will present data
suggesting that the paradigm of chronic
biotoxin-mediated illness may generalize to a
number of conditions involving toxin-form-
ing organisms. These organisms are increas-
ingly being viewed as potential human
health risks following direct contact or
through contamination of food, water,
and/or air. Because the Grand Rounds arti-
cle (1) is early in the course of presentations
on the basic concepts on biotoxin-mediated
illnesses, there must be discussion and scien-
tific debate regarding our observations. We
agree with Swinker and Burke that our
results must be confirmed in peer-reviewed
publications. The purpose of the Grand
Rounds article (1), our recent article (13), and
the Web site was to introduce a series of new
concepts to the academic community, prima-
ry-care physicians, and patients as part of a
teaching and research-promoting process.
Corrections and modifications will be made
to the Web site as time and resources allow.
In their letter, Swinker and Burke refer
to an advertisement for Shoemaker’s book,
Desperation Medicine (20). Cases support-
ing the hypothesis of generalization of a
PEAS-like illness to patients with exposure
to a variety of other biotoxin-producing
organisms are described in Desperation
Medicine (20). The book describes how
symptoms in biotoxin-exposed patients stem
from multiple system involvement, with
day-to-day variation; there are no days in
which affected patients are free from all
symptoms. Taken alone, each symptom is
nondiagnostic. Taken as a whole, however,
as presented in the Grand Rounds article
(1), the symptom complexes in patients who
have particular environmental exposures and
a distinct deficit in VCS are an important
component in developing standard-of-care
guidelines for the treating physician who
must attempt diagnosis. The physician must
take complete medical and potential biotox-
in exposure histories and thoroughly charac-
terize the patient’s symptom profile, not
relying on volunteered self-reports or a sim-
ple check-list. The physician may then iden-
tify the environmental exposure(s) associated
with the illness, as well as those that are not,
document the presence or absence of con-
founding neurotoxin exposures, administer
clinical and laboratory tests of potentially
confounding factors, and properly measure
VCS to determine whether there is a deficit
that is greatest at the mid-spatial frequencies.
When clinical criteria for the likely presence
of a biotoxin-mediated illness are met,
prompt and predictable resolution of the
symptom complex and VCS recovery, coin-
cident with initiation of CSM treatment
according to protocol, supports the diagnosis
of chronic biotoxin-mediated illness. The
usefulness of our case definition is particu-
larly well demonstrated in patients with
chronic illness that is unresponsive to previ-
ous treatments. We hope that acutely and
chronically ill patients of all physicians will
benefit from our new approach to diagnos-
ing and treating the emerging health risk of
biotoxin-induced illness.
H. Kenneth Hudnell
U.S. Environmental Protection Agency
Research Triangle Park, North Carolina
E-mail: hudnell.ken@epa.gov
Ritchie C. Shoemaker
McCready Outpatient Service Center
Pocomoke City, Maryland
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